1. Preclinical models for precision oncology
   Maider Ibarrola-Villava et al, 2018, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
2. Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies
   Sabrina Rizzolio et al, 2018 CrossRef
3. OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth
   Rheal A. Towner et al, 2019, Translational Oncology CrossRef
4. IGF signalling in germ cells and testicular germ cell tumours: roles and therapeutic approaches
   J. Selfe et al, 2019, Andrologia CrossRef
5. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
   Sean P. Kennedy et al, 2020, Oncogene CrossRef
6. ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment
   Ruibin Yi et al, 2020, Front. Genet. CrossRef
7. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
   Serena Di Cosimo et al, 2020, Breast Cancer Res CrossRef
8. Current trends in the treatment of HR+/HER2+ breast cancer
   Charlene Kay et al, 2021, Future Oncology CrossRef
9. Novel Hybrid Conjugates with Dual Estrogen Receptor α Degradation and Histone Deacetylase Inhibitory Activities for Breast Cancer Therapy
   Chenxi Zhao et al, 2021, Bioorganic & Medicinal Chemistry CrossRef
10. Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
    Lun Li et al, 2021, Front. Oncol. CrossRef
11. Evaluation of protein functionalized gold nanoparticles to improve tamoxifen delivery: synthesis, characterization, and biocompatibility on breast cancer cells
    Oznur Akbal Vural, 2021, International Journal of Polymeric Materials and Polymeric Biomaterials CrossRef
12. Recent advances and limitations in the application of kahalalides for the control of cancer
    Scott Wyer et al, 2022, Biomedicine & Pharmacotherapy CrossRef
13. Drugging IGF-1R in cancer: New insights and emerging opportunities
    Panpan Wang et al, 2022, Genes & Diseases CrossRef
14. Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer
    Adam L. Maddox et al, 2022, Cancers CrossRef
15. Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
    Mark Pegram et al, 2023, npj Breast Cancer CrossRef
16. Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2+ breast cancer
    Donna O. Debets et al, 2023, Cell Reports Medicine CrossRef
17. PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
    Xiaoyu Liu et al, 2023, World J Surg Onc CrossRef
18. Multiple receptor tyrosine kinases regulate dengue infection of hepatocytes
    Natasha M. Bourgeois et al, 2024, Front. Cell. Infect. Microbiol. CrossRef
19. Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions
    Andisyah Putri Sekar et al, 2024, Breast Cancer�(Auckl) CrossRef
20. Bioinformatics and In Vitro Study Reveals ERα as The Potential Target Gene of Honokiol to Enhance Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer Cells
    I Made Rhamanadana Putra et al, 2024, Computational Biology and Chemistry CrossRef
21. null
    Esteban Acosta-Ramos et al, 2024 CrossRef